Posted by Michael Wonder on 21 Aug 2018
Proposal to change the funded brand of epoetin alfa
21 August 2018 - PHARMAC is seeking feedback on a proposed change to the funded brand of epoetin alfa [erythropoietin alfa] injections used in the treatment of chronic renal failure and myelodysplasia.
- The funded brand would change from Eprex (supplied by Janssen) to Binocrit (supplied by Novartis) following a transition period starting on 1 February 2019;
- From the end of the transition period, Binocrit would be the only funded brand in both the community and hospital settings.
